FDA Approves New Quadrivalent Influenza Vaccine

The FDA has approved Afluria Quadrivalent (influenza vaccine), for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.

Afluria Quadrivalent is available in single-dose, preservative-free pre-filled syringes.

Afluria Quadrivalent demonstrated non-inferiority to 2 comparators in a randomized, double-blind, active-controlled clinical trial of 3449 participants aged 18 years and older.

Afluria Quadrivalent is contraindicated in individuals with severe allergic reactions to components of the vaccine, including egg protein.

Common adverse reactions include injection site pain, headache, fatigue, and myalgia.

—Michael Potts

Reference:

Sequirus. Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older. [press release]. August 29, 2016. http://www.prnewswire.com/news-releases/seqirus-receives-fda-approval-for-afluria-quadrivalent-influenza-vaccine-for-people-18-years-of-age-and-older-300319234.html